RxDoctor Payments Data

Niloufar Ghadiri, MD

Internal Medicine · Houston, TXNPI 1629159652

Payments from drug & device makers

$9,117in general payments, 2019–2025

Across 577 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$929
  • Amgen$786
  • Pfizer$728
  • Lilly USA, LLC$722
  • AbbVie$565
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$9,099100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,117 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$146,375
Medicare patients
302
Services billed
1,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$177,360
JardianceEmpagliflozin29$47,582
FarxigaDapagliflozin Propanediol25$33,427
MyrbetriqMirabegron40$33,017
MounjaroTirzepatide18$24,863
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$22,328
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$22,048
EliquisApixaban28$21,214
Tresiba Flextouch U-200Insulin Degludec22$18,424
JanuviaSitagliptin Phosphate12$13,434
Levothyroxine Sodium428$5,103
Rosuvastatin Calcium287$5,093
Atorvastatin Calcium515$4,821
SynthroidLevothyroxine Sodium77$4,742
Tiotropium Bromide11$4,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,760$177,360130 claims
Boehringer IngelheimJardiance$291$47,58229 claims
AstraZenecaFarxiga, Symbicort$929$36,36536 claims
Astellas Pharma US IncMyrbetriq$122$33,01740 claims
Lilly USA, LLCMounjaro$722$24,86318 claims
PfizerEliquis, Paxlovid$728$22,64442 claims
GSKTrelegy Ellipta$359$22,32833 claims
MerckJanuvia$452$13,43412 claims
AbbVieSynthroid$565$4,74277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →